Novartis AG (0QLR) Price & Analysis

Compare

11 Followers

0QLR Stock Chart & Stats

CHF104.73

CHF0.25(0.27%)

At close: Jan 08 4:00 PM EST

CHF104.73

CHF0.25(0.27%)

Day’s Range― - ―

52-Week RangeCHF81.22 - CHF106.86

Previous CloseN/A

Volume210.36K

Average Volume (3M)1.02M

Market Cap

CHF193.14B

Enterprise ValueCHF208.96B

Total Cash (Recent Filing)CHF9.75B

Total Debt (Recent Filing)CHF32.02B

Price to Earnings (P/E)16.3

Beta0.72

Next Earnings

Feb 04, 2026

EPS Estimate

1.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.82

Shares Outstanding2,112,421,900

10 Day Avg. Volume801,914

30 Day Avg. Volume1,022,628

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)4.47

Price to Sales (P/S)3.81

P/FCF Ratio14.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF103.40

Price Target Upside-1.27% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering12

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pipeline SuccessPotential continued pipeline success may improve confidence in Novartis's mid-term guides and ability to offset larger losses.

Product LaunchesSeveral new product launches have been successful, and more are likely to contribute positively to the company's growth.

Sales GrowthNovartis has upgraded its sales growth forecast with a new CAGR of 5-6%, implying higher future sales than previously expected.

Bears Say

Clinical FeedbackKOL compared ianalumab Sjogren’s launch to prior Benlysta in Lupus, where there was excitement for one approved agent but adoption ultimately disappointed given efficacy.

Earnings ImpactThe company's earnings before interest and taxes (EBIT) and earnings per share (EPS) are anticipated to be impacted negatively by Avidity dilution.

Valuation ConcernsDespite a promising pipeline and growth potential, the analyst maintains a Neutral rating on valuation, suggesting concerns over the stock's current price relative to its growth forecast.

Novartis AG News

Novartis upgraded to Buy from Neutral at BofA

BofA upgraded Novartis (NVS) to Buy from Neutral with a price target of CHF 117, up from CHF...

3d ago

NVS

Novartis receives FDA approval for Itvisma

Novartis (NVS) “announced that the US Food and Drug Administration has approved Itvisma, onasemnogene abeparvovec-brve, for the treatment...

4d ago

NVS

Labcorp appoints Victor Bulto to Board of Directors

Labcorp (LH) announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis’ executive leadership...

4d ago

NVS

Morning Movers: Walmart gains, Bath & Body Works plummets after Q3 reports

Stock futures are rising after Nvidia delivered another blockbuster earnings report and forward outlook. However, investors must still...

8d ago

ABT

Novartis sees +5%-6% sales CAGR cc for 2025-2030

Novartis (NVS) rolled forward its mid-term guidance to 2025-2030 with a sales CAGR of +5-6% cc. The updated...

8d ago

NVS

Novartis to build manufacturing hub in North Carolina

Novartis (NVS) announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with...

9d ago

NVS

Novartis announces Phase III trial for KLU156 met primary endpoint

Novartis (NVS) announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156. The novel...

15d ago

NVS

Dyne Therapeutics price target lowered to $11 from $13 at Oppenheimer

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Dyne Therapeutics (DYN) to $11 from $13 and...

16d ago

DYN

NVS

FDA appoints Richard Pazdur as Director of CDER

The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard...

17d ago

AZN

BMY

Novartis opens radioligand therapy manufacturing facility in California

Novartis (NVS) announced the opening of a new 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California. This site...

18d ago

NVS

Novartis AG: Strong Growth Potential Amid Patent Expirations with Robust Pipeline and Strategic Phase III Trials

In a report released today, Sachin Jain from Bank of America Securities upgraded Novartis AG to a Buy,...

3d ago

NVS

Novartis AG: Hold Rating Amid Moderate Growth and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities reiterated a Hold rating on Novartis AG, retaining the price...

8d ago

NVS

Cautious Hold on Novartis AG Amid Mixed Ianalumab Data and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novartis AG, retaining the price...

25d ago

NVS

Positive Long-Term Growth Outlook for Novartis AG Amid Temporary Setbacks

In a report released today, Thibault Boutherin from Morgan Stanley upgraded Novartis AG to a Buy, with a...

29d ago

NVS

0QLR FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest share price was CHF81.22 and its highest was CHF106.86 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is CHF193.14B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 68 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Oct 28, 2025. The company reported CHF1.819 earnings per share for the quarter, missing the consensus estimate of CHF1.837 by -CHF0.019.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG does not currently pay dividends.

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.59.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of CHF1.819 in its last earnings report, missing expectations of CHF1.837. Following the earnings report the stock price went down -3.255%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in GB:0QLR

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG (0QLR) Earnings & Revenues

Historic Earnings Reports

0QLR Stock 12 Month Forecast

Average Price Target

CHF103.40

▼(-1.27% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","121":"CHF121","93.25":"CHF93.3","102.5":"CHF102.5","111.75":"CHF111.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF103.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,93.25,102.5,111.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.428,101.01046153846154,102.59292307692307,104.17538461538462,105.75784615384615,107.34030769230769,108.92276923076923,110.50523076923076,112.08769230769231,113.67015384615385,115.25261538461538,116.83507692307693,118.41753846153846,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.428,99.73353846153846,100.03907692307692,100.34461538461538,100.65015384615384,100.9556923076923,101.26123076923076,101.56676923076924,101.8723076923077,102.17784615384616,102.48338461538462,102.78892307692308,103.09446153846154,{"y":103.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.428,98.70276923076923,97.97753846153846,97.2523076923077,96.52707692307692,95.80184615384616,95.07661538461538,94.35138461538462,93.62615384615384,92.90092307692308,92.1756923076923,91.45046153846154,90.72523076923076,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.762,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.974,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.508,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.266,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.147,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.695,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.747,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.815,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.469,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.334,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.428,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >